Mirum Pharmaceuticals, Inc. (MIRM) Phase 3 AZURE-1 Meets Primary Endpoint in HDV

Mirum said brelovitug met the primary endpoint at Week 24 in Phase 3 AZURE-1 for chronic HDV, with 56% (300 mg QW) and 45% (900 mg Q4W) responders vs 0% delayed (p<0.0001). Phase 2b showed deeper viral suppression and higher ALT normalization at 48 weeks.Material DetailsContext by AI AnalystThis is…